Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor (Q37528451)

20 August 2017

1 reference

title

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor (English)

1 reference

20 August 2017

1 reference

ChEBI release 2020-05-28

Lucy Garvey

1

1 reference

PubMed ID

19548857

20 August 2017

Alan Winston

series ordinal

2

1 reference

PubMed ID

19548857

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Investigational Drugs

20 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 August 2017

18

1 reference

20 August 2017

7

1 reference

20 August 2017

1035-1041

1 reference

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Pharmacokinetics of saquinavir co-administered with cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903055056

10.1517/13543780903055056

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19548857